Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARETHUSA: Pembrolizumab in mCRC
NCT03519412Phase 2Completed
- Sponsor
- IFOM
- Start
- Jan 2019
- Primary completion
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in colorectal cancer (CRC), sponsored by IFOM. Started Jan 2019; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03519412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03519412.